Issue 33 - Sep 4, 2020
  • Sharpless lays out a scenario for achieving 15% payline for RPGs

    NCAB approves ad hoc group to review TMIST, other detection trials impacted by COVID

    Budget increases in 2020 enabled NCI to boost funding for research project grants, pushing the payline up by two percentage points from last year’s level.

  • NCI: Targeted therapies for NSCLC drove sharp reduction in lung cancer mortality rate

    Sharp declines in mortality rates for non-small cell lung cancer in recent years are driven primarily by advances in treatment, NCI researchers concluded in a study published Aug. 12 in the New England Journal of Medicine.

  • Guest Editorial

    Delivering a cancer-free frontier during COVID-19

    As the only National Cancer Institute-designated Comprehensive Cancer Center in the Mountain West—a region that includes Utah, Idaho, Montana, Nevada, and Wyoming, covering 17% of the landmass of the continental United States—Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has a longstanding focus on improving cancer research, prevention, and treatment strategies for our patients and communities.

  • Mojo Sharpless, “world’s smartest dog,” shows off her talent to kids at NCI’s Camp Fantastic

    Earlier this summer, NCI Director Ned Sharpless faced a big challenge: produce a video for kids with cancer at Camp Fantastic.

  • In Brief

    • Patrick Hwu named president and CEO at Moffitt
    • Sylvester receives $120 million anonymous gift for cancer research
    • Tracy Onega named senior director of population sciences at Huntsman
    • Deirdre J. Cohen named director of GI Oncology at Mount Sinai, medical director of Cancer Clinical Trials Office at Tisch
    • $10.6 million federal grant to expand national proteomics resource at UAMS
    • Baylor receives SPORE renewal for breast cancer research
    • Charles Brenner named chair of City of Hope Department of Diabetes and Cancer Metabolism
    • Henry A. Pitt named chief of oncologic quality at Rutgers and RWJ
    • George Simon named executive director of Moffitt Cancer Center-AdventHealth joint Clinical Research Unit
    • Dorina Avram named vice chair of Immunology Department at Moffitt
    • CPRIT awards $114.7 million in grants
    • Ranjithmenon Muraleedharan receives $225,000 SebastianStrong grant for childhood brain cancer research
    • UArizona receives $2.2 million from NCI grant to study use of MRI to  find CRC metastases to the liver
    • Kristen Gonter-Aubin joins Florida Cancer Specialists and Research Institute
    • Gulden Mesara named chief communications and marketing officer at City of Hope
  • TCCL Logo

  • Clinical Roundup

    • NCCS survivorship data demonstrates prevailing “doctor knows best” mindset
    • Phase III VIALE-A trial of venetoclax combination meets OS endpoint in AML
    • Opdivo + Yervoy demonstrate durable survival benefit vs. chemotherapy in mesothelioma
    • Opdivo meets OS, PFS endpoints in phase III CheckMate-649 trial
    • Opdivo meets DFS endpoint in phase III CheckMate-577
    • Phase III IMpassion131 trial evaluating Tecentriq + paclitaxel does not meet PFS endpoint in metastatic TNBC
    • City of Hope clinical trial tests efficacy of delivering chemotherapy into the abdomen via a fine spray
    • Phase I/II relapsed or refractory Hodgkin lymphoma studies demonstrate high rate of durable complete responses
    • Study may refine predicted survival outcomes and treatment in younger adults with acute leukemia
    • CRUK-funded researchers use AI to analyze genetics of cancer
    • Genomic markers can identify brain tumor patients most likely to benefit from chemotherapy
    • ALK+ targeted therapy could prolong life for lung cancer patients
    • Real-world data analysis confirms sequential Gilotrif followed by osimertinib provided a median OS of nearly four years in NSCLC indication
    • Hormone therapy could treat small, T1a breast cancers
    • University of Kansas researchers launch COVID-19 study
    • University of Minnesota opens clinical trial for treatment of COVID-19
  • Drugs & Targets

    • Onureg oral therapy receives FDA approval for continued treatment for adults in first remission with AML
    • Kyprolis and Darzalex receives FDA approval for combination therapy for multiple myeloma
    • Blenrep receives FDA approval in relapsed or refractory multiple myeloma
    • Guardant360 CDx assay receives FDA approval as first liquid biopsy NGS companion diagnostic test
    • ClonoSEQ assay receives expanded FDA clearance to assess MRD in CLL
    • Melflufen receives FDA Priority Review for triple-class refractory multiple myeloma
    • FDA to evaluate cancer therapies in patients with brain metastases
    • FDA updates analysis of medical device reports of breast implant illness and breast implant-associated lymphoma
    • Dragonfly Therapeutics, BMS agree to exclusive global license for IL-12 investigational immunotherapy program
    • Thermo Fisher Scientific, Hengrui Therapeutics to develop companion diagnostic in NSCLC indication
  • NCI Trials

    NCI Trials for September 2020

    The National Cancer Institute approved the following clinical research studies last month. 

Issue 32 - Aug 7, 2020
Issue 31 - Jul 31, 2020